Guillain-Barre syndrome

This trial tests whether efgartigimod, a drug that lowers harmful antibody levels, can improve recovery in people with Guillain-Barré syndrome (GBS), a rare nerve condition that can cause weakness and paralysis. Adults aged 18 to 70 with recent GBS onset will receive either efgar…

Guillain-Barré syndrome (GBS) is a rare condition where the immune system attacks nerves, causing weakness that can progress to paralysis. Standard treatment is intravenous immunoglobulin (IVIg), but recovery is often slow. This phase 2 trial tests whether adding an experimental …

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …

This study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…

This early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …

This study tests whether blood samples collected at home using small capillary devices, like finger pricks, give the same results as traditional blood draws from a vein. Researchers will compare both methods in about 1,000 people with chronic conditions such as kidney disease, au…

This trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…

This study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …

This study looks closely at children admitted to a hospital with acute flaccid paralysis, a condition causing sudden muscle weakness or paralysis. Researchers will collect information from routine medical care to describe the clinical features, possible risk factors, and outcomes…

This study investigates whether nerve ultrasound patterns and biomarkers in blood and spinal fluid can predict how people with chronic inflammatory demyelinating polyneuropathy (CIDP) respond to treatment. Researchers will follow 30 adults with CIDP, including newly diagnosed and…

This study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …

This study will follow 1,550 adults with various neurological autoimmune diseases—like multiple sclerosis, myasthenia gravis, and autoimmune encephalitis—to see how these conditions progress and respond to treatments in everyday medical practice. Researchers will measure disabili…

This study will look at medical and lab factors that influence how children with Guillain-Barré syndrome recover. Researchers will follow 80 children to see which ones fully recover within 3 months. The goal is to create better ways to predict outcomes and guide treatment.